TYMP
ENSG00000025708
Target class
Enzyme
Chromosome
22
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- TYMP
- Gene name
- Thymidine phosphorylase
- Gene symbol
- TYMP
- Protein name
- Thymidine phosphorylase (TP) (EC 2.4.2.4) (Gliostatin) (Platelet-derived endothelial cell growth factor) (PD-ECGF) (TdRPase)
- MNGIE
- ECGF1
- Gene biotype
- Protein coding
- Gene family
- Minor histocompatibility antigens
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 330.6
- Tissue specificity (Gini)
- 0.521
- Tissue specificity (tau)
- 0.848
- KEGG gene identifiers
- hsa:1890
- Protein interaction confidence
- 0.856375
- Protein interaction partners
- 48
- R-HSA-73614
- R-HSA-73621
- End position
- 50530326
- Start position
- 50525752
- Chromosome
- 22
- Strand
- Reverse
- Cytosol
- Golgi apparatus
- Nuclear bodies
- Tissue specificity (tau)
- 0.847999
- Expression inequality (Gini)
- 0.520518
Expression in transcripts per million
- Whole Blood
- 330.6
- Lung
- 260.64
- Spleen
- 215.25
- Adipose - Subcutaneous
- 139.96
- Adipose - Visceral (Omentum)
- 116.37
Expression in transcripts per million
- Whole Blood330.6
- Lung260.64
- Spleen215.25
- Adipose - Subcutaneous139.96
- Adipose - Visceral (Omentum)116.37
- Cells - EBV-transformed lymphocytes98.9
- Breast - Mammary Tissue98.68
- Minor Salivary Gland96.84
- Esophagus - Mucosa95.18
- Thyroid93.53
- Fallopian Tube87.1
- Artery - Coronary75.84
- Small Intestine - Terminal Ileum73.83
- Cervix - Ectocervix70.13
- Vagina68.26
- Liver66.98
- Kidney - Medulla65.58
- Prostate63.96
- Cervix - Endocervix60.4
- Artery - Aorta59.03
- Skin - Not Sun Exposed (Suprapubic)57.74
- Nerve - Tibial49.47
- Skin - Sun Exposed (Lower leg)48.77
- Kidney - Cortex41.67
- Colon - Transverse41.28
And 29 more, listed on the interactive page.
Biological processes
- GO:0006213
Cellular components
- GO:0005829
- GO:0005515
- GO:0009032
- GO:0042803
Related records
Trials (100)
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
- A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
- A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
- A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)
- A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
- A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
- A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
- A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects
- A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
Drugs (2)
- Tipiracil Thymidine phosphorylase inhibitor
- Tipiracil hydrochloride Thymidine phosphorylase inhibitor